{{Cleanup|reason=the content/scope are not encyclopedic for an important anesthetic, and sources are often primary/lacking|date=August 2014}}
{{drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 464389790
| IUPAC_name = 1,1,1,3,3,3-Hexafluoro-2-(fluoromethoxy)propane
| image = Sevoflurane.svg
| image2 = Sevoflurane-3D-balls.png

<!--Clinical data-->
| tradename = Sojourn, Ultane, Sevorane
| Drugs.com = {{drugs.com|CDI|sevoflurane}}
| pregnancy_AU = B2
| pregnancy_US = B
| legal_AU = S4
| legal_UK = POM
| legal_US = Rx-only
| legal_status = 
| routes_of_administration = inhaled

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life =

<!--Identifiers-->
| IUPHAR_ligand = 7296
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 28523-86-6
| ATC_prefix = N01
| ATC_suffix = AB08
| ATC_supplemental = 
| PubChem = 5206
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01236
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 5017
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 38LVP0K73A
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00547
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 9130
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1200694

<!--Chemical data-->
| C=4 | H=3 | F=7 | O=1 
| molecular_weight = 200.055 g/mol
| smiles = FC(F)(F)C(OCF)C(F)(F)F
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C4H3F7O/c5-1-12-2(3(6,7)8)4(9,10)11/h2H,1H2
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = DFEYYRMXOJXZRJ-UHFFFAOYSA-N
| boiling_point = 58.5
}}

'''Sevoflurane''' (1,1,1,3,3,3-hexafluoro-2-(fluoromethoxy)propane; synonym, ''fluoromethyl hexafluoroisopropyl ether''), is a sweet-smelling, nonflammable, [[halogenated ether|highly fluorinated methyl isopropyl ether]] used as an [[inhalational anaesthetic]] for induction and maintenance of [[general anesthesia]]. After [[desflurane]], it is the volatile anesthetic with the fastest onset and offset.<ref>{{cite journal |author1=Sakai EM |author2=Connolly LA |author3=Klauck JA |title=Inhalation anesthesiology and volatile liquid anesthetics: focus on isoflurane, desflurane, and sevoflurane |journal=Pharmacotherapy |volume=25 |issue=12 |pages=1773–88 |date=December 2005 |pmid=16305297 |doi=10.1592/phco.2005.25.12.1773 |url=http://www.atypon-link.com/doi/abs/10.1592/phco.2005.25.12.1773}}</ref>

It is one of the most commonly used [[volatility (chemistry)|volatile]] anesthetic agents, particularly for outpatient anesthesia,<ref name=Livertox>Livertox: Clinical and Research Information on Drug-Induced Liver Injury (2014) "Drug Record: Sevoflurane", U.S. National Library of Medicine, 2 July 2014 update, see [http://livertox.nih.gov/Sevoflurane.htm], accessed 15 August 2014.</ref>  across all ages, as well as in veterinary medicine. Together with [[desflurane]], sevoflurane is replacing [[isoflurane]] and [[halothane]] in modern [[anesthesiology]]. It is often administered in a mixture of [[nitrous oxide]] and oxygen.

<!-- Side effects -->
Sevoflurane "has an excellent safety record",<ref name=Livertox/> but is under review for potential [[neurotoxicity]], especially relevant to administration in infants and children, and rare reports similar to [[halothane]] [[hepatotoxicity]].<ref name=Livertox/> Sevoflurane is the preferred agent for mask induction due to its lesser irritation to [[mucous membrane]]s.

<!-- History, society, and culture -->
Sevoflurane was discovered by Ross Terrell<ref>{{cite journal|last=Burns|first=William|author2=Edmond I Eger II |title=Ross C. Terrell, PhD, an Anesthetic Pioneer|journal=Anesth. Analg.|date=August 2011|volume=113|issue=2|pages=387–9|doi=10.1213/ane.0b013e3182222b8a}}</ref> and independently by Bernard M Regan. A detailed report of its development and properties appeared in 1975 in a paper authored by Richard Wallin, Bernard Regan, Martha Napoli and Ivan Stern. It was introduced into clinical practice initially in Japan in 1990. The rights for sevoflurane worldwide were held by [[AbbVie]]. It is now available as a [[generic drug]].

==Medical uses==
Sevoflurane is an inhaled anaesthetic that is often used to put children asleep for surgery.<ref name=Cos2014/> During the process of waking up from the [[medication]], it has been known to cause agitation and [[delirium]].<ref name=Cos2014/> It is not clear if this can be prevented.<ref name=Cos2014>{{cite journal|last1=Costi|first1=D|last2=Cyna|first2=AM|last3=Ahmed|first3=S|last4=Stephens|first4=K|last5=Strickland|first5=P|last6=Ellwood|first6=J|last7=Larsson|first7=JN|last8=Chooi|first8=C|last9=Burgoyne|first9=LL|last10=Middleton|first10=P|title=Effects of sevoflurane versus other general anaesthesia on emergence agitation in children.|journal=The Cochrane database of systematic reviews|date=Sep 12, 2014|volume=9|pages=CD007084|pmid=25212274|doi=10.1002/14651858.CD007084.pub2}}</ref>

==Adverse effects==
Studies examining a current significant health concern, anesthetic-induced neurotoxicity (including with sevoflurane, and especially with children and infants) are "fraught with confounders, and many are underpowered statistically", and so are argued to need "further data... to either support or refute the potential connection".<ref>{{cite journal | last1 = Vlisides | first1 = P | last2 = Xie | first2 = Z. | year = 2012 | title = Neurotoxicity of general anesthetics: an update | url = | journal = Curr Pharm Design | volume = 18 | issue = 38| pages = 6232–40 | pmid = 22762477 | doi=10.2174/138161212803832344}}</ref>

Concern regarding the safety of anaesthesia is especially acute with regard to children and infants, where preclinical evidence from relevant animal models suggest that common clinically important agents, including sevoflurane, may be neurotoxic to the developing brain, and so cause neurobehavioural abnormalities in the long term; two large-scale clinical studies (PANDA and GAS) were ongoing as of 2010, in hope of supplying "significant [further] information" on neurodevelopmental effects of general anaesthesia in infants and young children, including where sevoflurane is used.<ref>{{cite journal | last1 = Sun | first1 = L. | year = 2010 | title = Early childhood general anaesthesia exposure and neurocognitive development | journal = Br J Anaesth | volume = 105 | issue = Suppl 1| pages = i61–8 | doi = 10.1093/bja/aeq302 | pmid = 21148656 | pmc=3000523}}</ref>

==Pharmacology==
The exact mechanism of the action of general anaesthetics have not been delineated.<ref>{{cite web|url=http://www.scientificamerican.com/article/how-does-anesthesia-work/ |title=How does anesthesia work? |publisher=[[Scientific American]] |date=7 February 2005 |accessdate=30 June 2016}}</ref> Sevoflurane is thought to potentially act as a [[positive allosteric modulator]] of the [[GABAA receptor|GABA<sub>A</sub> receptor]].<ref name="SchüttlerSchwilden2008">{{cite book|author1=Jürgen Schüttler|author2=Helmut Schwilden|title=Modern Anesthetics|url=https://books.google.com/books?id=JpkkWhPbh2QC&pg=PA32|date=8 January 2008|publisher=Springer Science & Business Media|isbn=978-3-540-74806-9|pages=32–}}</ref> However, it also acts as an [[NMDA receptor antagonist]],<ref name="BrosnanThiesen2012">{{cite journal|last1=Brosnan|first1=Robert J|last2=Thiesen|first2=Roberto|title=Increased NMDA receptor inhibition at an increased Sevoflurane MAC|journal=BMC Anesthesiology|volume=12|issue=1|year=2012|page=9|issn=1471-2253|doi=10.1186/1471-2253-12-9}}</ref> potentiates [[glycine receptor]] currents,<ref name="SchüttlerSchwilden2008" /> and inhibits [[nicotinic acetylcholine receptor|nACh]]<ref name="Dort2008">{{cite book|author=Christa J. Van Dort|title=Regulation of Arousal by Adenosine A(1) and A(2A) Receptors in the Prefrontal Cortex of C57BL/6J Mouse|url=https://books.google.com/books?id=YZJ5NM_a3N0C&pg=PA120|year=2008|publisher=ProQuest|isbn=978-0-549-99431-2|pages=120–}}</ref> and [[5-HT3 receptor|5-HT<sub>3</sub> receptor]] currents.<ref name="SchüttlerSchwilden2008B">{{cite book|author1=Jürgen Schüttler|author2=Helmut Schwilden|title=Modern Anesthetics|url=https://books.google.com/books?id=JpkkWhPbh2QC&pg=PA74|date=8 January 2008|publisher=Springer Science & Business Media|isbn=978-3-540-74806-9|pages=74–}}</ref><ref name="pmid11873047">{{cite journal |author1=Suzuki T |author2=Koyama H |author3=Sugimoto M |author4=Uchida I |author5=Mashimo T | title = The diverse actions of volatile and gaseous anesthetics on human-cloned 5-hydroxytryptamine3 receptors expressed in Xenopus oocytes | journal = Anesthesiology | volume = 96 | issue = 3 | pages = 699–704 |date=March 2002  | pmid = 11873047 | doi = 10.1097/00000542-200203000-00028| url = http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0003-3022&volume=96&issue=3&spage=699}}</ref><ref name="pmid20885002">{{cite journal |author1=Hang LH |author2=Shao DH |author3=Wang H |author4=Yang JP | title = Involvement of 5-hydroxytryptamine type 3 receptors in sevoflurane-induced hypnotic and analgesic effects in mice | journal = Pharmacol Rep | volume = 62 | issue = 4 | pages = 621–6 | year = 2010 | pmid = 20885002 | doi = 10.1016/s1734-1140(10)70319-4| url = http://www.if-pan.krakow.pl/pjp/pdf/2010/4_621.pdf}}</ref>

==Physical properties==
{|
|-
|[[Boiling point]]: ||align=right| 58.6&nbsp;°C || (at 101.325 kPa)
|-
|[[Density]]: ||align=right| 1.517&ndash;1.522 g/cm³|| (at 20&nbsp;°C)
|-
|[[Minimum alveolar concentration|MAC]] : ||align=right|  2.1 vol % ||
|-
|[[Molecular weight]]: ||align=right| 200 [[unified atomic mass unit|u]]||
|-
|[[Vapor pressure]]: ||align=right| 157 mmHg (20.9&nbsp;kPa)|| (at 20&nbsp;°C)
|-
| ||align=right|197 mmHg (26.3&nbsp;kPa)  || (at 25&nbsp;°C)
|-
| ||align=right|317 mmHg (42.3 kPa)  || (at 36&nbsp;°C)
|-
|[[blood/gas partition coefficient|Blood:Gas partition coefficient]]: ||align=right| 0.68||
|-
|Oil:Gas partition coefficient: ||align=right| 47||
|
|}

==References==
{{Reflist|30em}}

==Further reading==
*{{cite journal |author1=Patel SS |author2=Goa KL |title=Sevoflurane. A review of its pharmacodynamic and pharmacokinetic properties and its clinical use in general anaesthesia |journal=Drugs |volume=51 |issue=4 |pages=658–700 |date=April 1996 |pmid=8706599 |url=http://adisonline.com/drugs/Abstract/1996/51040/Sevoflurane__A_Review_of_its_Pharmacodynamic_and.9.aspx |doi=10.2165/00003495-199651040-00009}}<br/>{{cite journal |title=Erratum |journal=Drugs |volume=52 |issue=2 |page=253 |date=August 1996 |url=http://adisonline.com/drugs/toc/1996/52020#-832002973|doi=10.1007/bf03257493 }}
* {{cite journal|author=Wallin, Richard F., Regan, Bernard M., Napoli, Martha D., Stern, Ivan j.|title=Sevoflurane: A New Inhalational Anesthetic Agent|journal=Anesthesia and Analgesia|volume=54|number=6|pages=758–766|date=Nov–Dec 1975|doi=10.1213/00000539-197511000-00021}}

==External links==
*{{cite web |url=http://www.priory.com/anaesthesia/propofol_and_sevoflurane.htm |title=Propofol and Sevoflurane Anesthesia }}

{{General anesthetics}}
{{Navboxes
| title = [[Pharmacodynamics]]
| titlestyle = background:#ccccff
| list1 = 
{{GABAA receptor modulators}}
{{Glycine receptor modulators}}
{{Ionotropic glutamate receptor modulators}}
{{Nicotinic acetylcholine receptor modulators}}
{{Serotonin receptor modulators}}
}}

[[Category:General anesthetics]]
[[Category:Ethers]]
[[Category:Organofluorides]]
[[Category:GABAA receptor positive allosteric modulators]]
[[Category:Glycine receptor agonists]]
[[Category:Nicotinic antagonists]]
[[Category:NMDA receptor antagonists]]
[[Category:5-HT3 antagonists]]
[[Category:Fluranes]]
[[Category:Trifluoromethyl compounds]]